Insight Molecular Diagnostics Inc. (IMDX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$2.85

From 52W high−68.75%

Volume154092.00

Market cap$86.72M

P/E (TTM)—

P/S (TTM)51.9x

Div yield—

Key dataNov 4, 2026

Open

$2.85

From 52W high

−68.75%

Volume

154092.00

Market cap

$86.72M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.5x

P/E (TTM)

—

RSI (14)

39.9

MomentumView details →

1D Return

−3.28%

YTD Return

−62.29%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.5x

EV/Sales

42.9x

P/S (TTM)

51.9x

P/B (TTM)

−4.1x

ProfitabilityView details →

Gross Margin

11.17%

Net Margin

−2955.63%

EBITDA Margin

−2803.47%

ROE (TTM)

231.74%

ROA (TTM)

−167.64%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

−60.77%

EPS YoY

+56.27%

FCF YoY

−30.29%

Revenue CAGR 3Y

+61.76%

EPS CAGR 3Y

+64.60%

EBITDA YoY

+23.69%

MomentumView details →

1D Return

−3.28%

YTD Return

−62.29%

1Y Return

−57.54%

RSI (14)

39.9

vs 50D SMA

−19.91%

vs 200D SMA

−39.57%

Capital & dividendView details →

Debt/Equity

−0.12x

Current Ratio

2.00x

Quick Ratio

1.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.31

EPS Surprise

−22.07%

Beats (12Q)

7/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

42.20%

Rev Surprise

−45.37%

Financials snapshotView financials →

Revenue (TTM)

1.67M

Net Income (TTM)

−49.36M

Op. CF (TTM)

−26.95M

Next earningsNov 9, 2026 →

Latest newsMore news →

Insight Molecular Diagnostics Inc. appointed Donnie Purto as Senior Vice President of Sales.21d ago

Insight Molecular Diagnostics Inc. amended its merger agreement with Chronix to replace earnout consideration with a 10% royalty on CNI Monitor sales, payable until a CNI Monitor sale or IP expiration.44d ago

Similar companies

NeurAxis, Inc.NRXS Tonix Pharmaceuticals Holding Corp.TNXP Rallybio CorporationRLYB Genelux CorporationGNLX Tenaya Therapeutics, Inc.TNYA Lixte Biotechnology Holdings, Inc.LIXT Find similar companies →

Latest newsMore news →

Insight Molecular Diagnostics Inc. appointed Donnie Purto as Senior Vice President of Sales.21d ago Insight Molecular Diagnostics Inc. amended its merger agreement with Chronix to replace earnout consideration with a 10% royalty on CNI Monitor sales, payable until a CNI Monitor sale or IP expiration.44d ago